These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15776578)

  • 21. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
    Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
    Stephan C; Schnorr D; Loening SA; Jung K
    Eur Urol; 2005 Dec; 48(6):1059-60; author reply 1060-1. PubMed ID: 16260082
    [No Abstract]   [Full Text] [Related]  

  • 23. Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials.
    Collette L
    Eur Urol; 2008 Jan; 53(1):6-9. PubMed ID: 17764823
    [No Abstract]   [Full Text] [Related]  

  • 24. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
    Sartor O
    J La State Med Soc; 2008; 160(2):99-100. PubMed ID: 18681353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [PSA test--one more time].
    Drøsdal HH
    Tidsskr Nor Laegeforen; 2005 May; 125(10):1384; author reply 1384. PubMed ID: 15909026
    [No Abstract]   [Full Text] [Related]  

  • 26. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
    Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
    Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prostate specific antigen: utilization modalities and interpretation].
    Hannoun-Levi JM; Ginot A; Thariat J
    Cancer Radiother; 2008 Dec; 12(8):848-55. PubMed ID: 18539498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Increased PSA level in one person--myself!].
    Lakartidningen; 2005 Sep 26-Oct 2; 102(39):2788. PubMed ID: 16245557
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostate-specific antigen doubling time as a prognostic marker in prostate cancer.
    Eastham JA
    Nat Clin Pract Urol; 2005 Oct; 2(10):482-91. PubMed ID: 16474622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.
    D'Amico AV
    J Clin Oncol; 2008 Feb; 26(6):823-4. PubMed ID: 18281649
    [No Abstract]   [Full Text] [Related]  

  • 32. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.
    Kobayashi M; Kuramoto H; Ota J; Fujimoto N
    Int J Urol; 2006 Jul; 13(7):1019-21. PubMed ID: 16882080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A medical reveals a slightly raised PSA.
    Spira M; Kirby M; Williams G
    Practitioner; 1997 Jun; 241(1575):303, 307-10, 313 passim. PubMed ID: 9230511
    [No Abstract]   [Full Text] [Related]  

  • 34. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
    Lehrer S; Diamond EJ; Mamkine B; Droller MJ; Stone NN; Stock RG
    BJU Int; 2005 May; 95(7):961-2. PubMed ID: 15839913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comments on the PSA in primary health care: survey results in more "losers" than "winners"].
    Bratt O
    Lakartidningen; 2003 Nov; 100(48):4014-5. PubMed ID: 14717100
    [No Abstract]   [Full Text] [Related]  

  • 36. [Elevated PSA--what to do?].
    Machemer H; Rohde D
    MMW Fortschr Med; 2008 Oct; 150(44):38-9. PubMed ID: 19024490
    [No Abstract]   [Full Text] [Related]  

  • 37. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Singh A
    Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
    [No Abstract]   [Full Text] [Related]  

  • 38. [The National Board of Health and Welfare's guidelines for prostatic cancer care. PSA test screening--only for well-informed men].
    Bratt O; Damber JE; Kärvinge C; Malm T; Hensjö LO; Hyttsten E
    Lakartidningen; 2008 Feb 20-26; 105(8):524-8. PubMed ID: 18363292
    [No Abstract]   [Full Text] [Related]  

  • 39. [PSA kinetics after total prostatectomy].
    Riedinger JM; Eche N; Fulla Y; Thuillier F
    Ann Biol Clin (Paris); 2009; 67(1):39-46. PubMed ID: 19189884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
    Saito T; Hara N; Kitamura Y; Komatsubara S
    Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.